Instant Download
Your unique download link appears right after you complete your purchase, and is also sent instantly to the email address you provided.
Save up to 70% on all courses, discount auto applied
Oregon Health & Science 8th Annual MS and CNS Neuroimmunology Symposium 2025
Oregon Health & Science 8th Annual MS and CNS Neuroimmunology Symposium 2025
Regular price
$13.00 USD
Regular price
Sale price
$13.00 USD
Couldn't load pickup availability
Multi Speciality
Multi Speciality
Yes
Primary Speciality
Primary Speciality
Organ-System-Specialties
Target Audience
Target Audience
neurologists, neuroimmunologists, rheumatologists, ophthalmologists, neurosurgeons, physicians
Content Type
Content Type
Mixed (Video + PDF)
Size
Size
Mixed (Video + PDF)
Year
Year
Provider/Organization
Provider/Organization
Other
- Target Audience: neurologists, neuroimmunologists, rheumatologists, ophthalmologists, neurosurgeons, physicians
- Sample video: contact me for sample video
- Information:
October 11, 2025
Virtual symposium
This accredited half-day symposium provides health care professionals information to identify, refer, treat and/or implement practice changes to improve the care of patients with neuroimmunological disorders. Specific disorders discussed this year include a 2 part update on Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy, stopping therapy in MS, Transverse myelitis, Anti-Amyloid Therapies, and managing fatigue.
Who should attend
Neurologists, neuroimmunologists, rheumatologists, ophthalmologists, neurosurgeons, physicians, nurse practitioners, rehabilitation including physical and occupational therapists, researchers, and other medical professionals in the field of neuroimmunological disorders are invited to attend.
Learning objectives
Identify current diagnostic criteria and treatment updates for myasthenia gravis
Recognize clinical features and apply updated management strategies for chronic inflammatory demyelinating polyneuropathy (CIDP)
Evaluate appropriate criteria and timing for discontinuing disease-modifying therapies in multiple sclerosis patients
Analyze case-based presentations of transverse myelitis to improve diagnostic accuracy and treatment decision-making
Implement evidence-based strategies for managing fatigue in patients with multiple sclerosis
Assess patient eligibility and monitoring requirements for anti-amyloid therapies in early-stage Alzheimer’s disease
- Topics:
01 Neuromuscular Part I Myasthenia Gravis – Updates
02 Neuromuscular Part II Chronic Inflammatory Demyelinating Polyneuropathy – Updates
03 When to stop therapy, discontinuing DMT in MS
04 Transverse myelitis, a case-based discussion
05 Managing Fatigue in MS
06 Anti-Amyloid Therapies for the Treatment of Early-Stage Alzheimer’s disease
